Woodline Partners’s Eledon Pharmaceuticals ELDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.53M | Hold |
1,671,822
| – | – | 0.02% | 586 |
|
|
2025
Q1 | $5.67M | Hold |
1,671,822
| – | – | 0.04% | 476 |
|
|
2024
Q4 | $6.89M | Buy |
1,671,822
+828,930
| +98% | +$3.42M | 0.05% | 421 |
|
|
2024
Q3 | $2.1M | Buy |
842,892
+167,649
| +25% | +$417K | 0.02% | 471 |
|
|
2024
Q2 | $1.78M | Buy |
675,243
+23,304
| +4% | +$61.5K | 0.02% | 427 |
|
|
2024
Q1 | $1.34M | Sell |
651,939
-37,401
| -5% | -$77K | 0.01% | 444 |
|
|
2023
Q4 | $1.24M | Buy |
689,340
+85,347
| +14% | +$154K | 0.01% | 395 |
|
|
2023
Q3 | $827K | Buy |
603,993
+87,318
| +17% | +$120K | 0.01% | 461 |
|
|
2023
Q2 | $708K | Hold |
516,675
| – | – | 0.01% | 510 |
|
|
2023
Q1 | $1.22M | Hold |
516,675
| – | – | 0.02% | 459 |
|
|
2022
Q4 | $1.18M | Hold |
516,675
| – | – | 0.02% | 528 |
|
|
2022
Q3 | $1.43M | Hold |
516,675
| – | – | 0.02% | 503 |
|
|
2022
Q2 | $1.26M | Sell |
516,675
-156,463
| -23% | -$382K | 0.02% | 488 |
|
|
2022
Q1 | $2.65M | Sell |
673,138
-108,238
| -14% | -$426K | 0.04% | 339 |
|
|
2021
Q4 | $3.45M | Hold |
781,376
| – | – | 0.05% | 335 |
|
|
2021
Q3 | $4.83M | Sell |
781,376
-76,069
| -9% | -$470K | 0.08% | 256 |
|
|
2021
Q2 | $6.78M | Sell |
857,445
-33,610
| -4% | -$266K | 0.13% | 187 |
|
|
2021
Q1 | $9.53M | Sell |
891,055
-1,500
| -0.2% | -$16.1K | 0.21% | 123 |
|
|
2020
Q4 | $13.7M | Buy |
+892,555
| New | +$13.7M | 0.36% | 86 |
|